STOCK TITAN

Gb Sciences Co-Publishes Study Demonstrating Efficacy of Its Proprietary Cannabinoid Mixtures for the Treatment of Parkinson's Disease

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Gb Sciences has co-published research in Frontiers in Pharmacology validating cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for treating symptoms of Parkinson's disease (PD). This innovative approach targets a growing market projected to reach $8.8 billion by 2026.

Dr. Andrea Small Howard highlighted the efficacy of these mixtures in reducing PD motor symptoms in animal models. The study utilized advanced methods at multiple research sites, paving the way for further preclinical testing and potential future human trials.

Positive
  • Co-published study validates cannabinoid ratios for Parkinson's disease treatment.
  • Market for Parkinson's disease treatments projected to grow to $8.8 billion by 2026.
  • Efficacy demonstrated in animal models, positioning Gb Sciences for future therapeutic contributions.
Negative
  • None.

As published in Frontiers in Pharmacology, the biopharmaceutical drug development firm's sponsored research has identified and validated cannabinoid ratio-controlled, Minimum Essential Mixtures (MEM) for the treatment of Parkinson's disease symptoms

LAS VEGAS, Oct. 10, 2022 (GLOBE NEWSWIRE) -- Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and drug development company, has co-published a study in the journal Frontiers in Pharmacology that demonstrates the efficacy of its proprietary cannabinoid-containing, minimum essential mixtures (MEM) for the treatment of Parkinson's disease (PD). There is a great clinical need for improved therapeutics, and the market for Parkinson's disease treatments is expected to grow to $8.8 billion by 2026.

"Our drug discovery process has identified promising ratio-controlled mixtures of cannabis-inspired compounds for the treatment of Parkinson's disease, which have proven effective at reducing Parkinsonian motor symptoms in an animal model of the disease," said Dr. Andrea Small Howard, President, Chief Science Officer, and Director of Gb Sciences. "This study allows us to continue addressing unmet clinical needs through the development of novel plant-inspired drugs, and positions Gb Sciences as a contributor to the expanding world of novel PD therapeutics."

For this Gb Sciences-sponsored study, the discovery research using cell models of Parkinson's disease was performed at Chaminade University (Honolulu, Hawai'i, USA), and the MEM refinement and validation research was performed in a zebrafish model of Parkinson's disease at the National Research Council of Canada (NRC). The study entitled "Identification of minimum essential therapeutic mixtures from Cannabis plant extracts by screening in cell and animal models of Parkinson's disease" was co-authored by Gb Sciences' own President and Chief Science Officer Andrea Small-Howard and her collaborators Michael G. Morash, Jessica Nixon, and Lee Ellis from the National Research Council of Canada; Lori M.N. Shimoda and Helen Turner from Chaminade University of Honolulu; and Alexander J. Stokes from the University of Hawai'i at Manoa (Manoa, Hawai'i, USA).

The sequentially reductionist process implemented in this multi-site study preserves some of the entourage-like effects of whole plant extracts while achieving "relative" simplicity within MEM that is a requirement for obtaining the manufacturing and quality control advantages of single-ingredient drugs. This paper identifies promising minimal essential mixtures of cannabinoids based on a step-wise, strategic approach to reducing the complexity of the plant secondary metabolome. The sequential use of in silico, in vitro, and medium throughput in vivo experimental systems has generated refined, de-risked mixtures that can now be tested in additional, higher-cost, preclinical model systems of PD.

Gb Sciences' Parkinson's therapeutics are currently being tested in a rodent model of Parkinson's disease at the University of Lethbridge, and these Parkinson's MEM have been formulated as Oral Dissolving Tablets in preparation for human clinical trials. The Company is preparing for the final rounds of toxicology and pharmacology testing as required for filing an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The "plant-inspired" active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:
Madeleine Moench
madeleine@newswire.com

Related Images






Image 1



This content was issued through the press release distribution service at Newswire.com.

Attachment


FAQ

What is the significance of the study published by Gb Sciences on October 10, 2022?

The study validates cannabinoid ratio-controlled Minimum Essential Mixtures for Parkinson's disease treatment, indicating potential therapeutic advancements.

How does the research by Gb Sciences impact the Parkinson's disease treatment market?

The research targets a growing market expected to reach $8.8 billion by 2026, suggesting significant commercial potential for successful therapeutics.

What are Minimum Essential Mixtures (MEM) in the context of Gb Sciences' research?

MEM refers to cannabinoid ratios identified by Gb Sciences that show efficacy in treating symptoms of Parkinson's disease.

Where was the research study on Parkinson's disease conducted?

The research was performed at Chaminade University in Hawaii and the National Research Council of Canada.

What are the next steps for the Parkinson's therapeutics developed by Gb Sciences?

The company is preparing for final toxicology and pharmacology testing necessary for an Investigational New Drug application.

GB SCIENCES INC

OTC:GBLX

GBLX Rankings

GBLX Latest News

GBLX Stock Data

2.56M
400.28M
12.22%
Biotechnology
Healthcare
Link
United States of America
Las Vegas